4//SEC Filing
Cole Douglas G. 4
Accession 0001415889-23-012136
CIK 0001821323other
Filed
Aug 10, 8:00 PM ET
Accepted
Aug 11, 4:10 PM ET
Size
8.7 KB
Accession
0001415889-23-012136
Insider Transaction Report
Form 4
Cole Douglas G.
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-08-11$5.00/sh−683$3,414→ 0 totalExercise: $9.92Exp: 2032-05-25→ Common Stock (683 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-11$6.64/sh−683$4,538→ 0 totalExercise: $8.28Exp: 2033-05-18→ Common Stock (683 underlying)
Footnotes (2)
- [F1]Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
- [F2]Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Documents
Issuer
Sigilon Therapeutics, Inc.
CIK 0001821323
Entity typeother
Related Parties
1- filerCIK 0001486373
Filing Metadata
- Form type
- 4
- Filed
- Aug 10, 8:00 PM ET
- Accepted
- Aug 11, 4:10 PM ET
- Size
- 8.7 KB